• About Us
    • Corporate Overview
    • Executive Leadership
      • Management team
      • Scientific Advisory Board
      • Board of Directors
      • Clinical Advisory Board
  • Our Science
    • Pipeline
      • Overview
      • AG-73305
      • AG-80308
      • AG-86893
    • Disease
      • Overview
      • DME
      • nAMD
      • Other Diseases
      • Pterygium
      • Dry Eye
    • Clinical Trial
  • Investor Relations
    • Investors
    • Press Release & Publications
    • Allgenesis In The News
  • Contact Us

Press Release & Publications

  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • News
  • All
  • 2015
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • 2023
  • All
  • admin
  • allgenesis
  • sky
2020-02-05

Allgenesis Receives Notice of Grant of Japanese Patent for anti-VEGF/Disintegrin Fusion Protein

Taipei, Taiwan/ February 4th, 2020 Allge […]
Do you like it?
Read more
2020-01-21

Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium

Taipei, Taiwan/ January 21st, 2020 Allge […]
Do you like it?
Read more
2019-11-14

Allgenesis Program Selected for RESI Taipei Innovation Challenge

Taipei, Taiwan/ November 14th, 2019 Allg […]
Do you like it?
Read more
2019-10-18

Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium

Taipei, Taiwan/ October 18th, 2019 Allge […]
Do you like it?
Read more
2019-09-25

Allgenesis Provides Timing Update of SURPH Phase 2a Clinical Trial for AG-86893 for the Treatment of Pterygium

September 25th, 2019 Allgenesis Biothera […]
Do you like it?
Read more
2019-06-11

CEO Dr. Cherukury Interviewed by Macular Degeneration Foundation at the 2019 ARVO Conference

June 11th, 2019 Allgenesis In the News: […]
Do you like it?
Read more
Load more

9F.-3, No.760, Sec. 4, Bade Rd.,
Songshan Dist., Taipei City 105,
Taiwan (R.O.C.)

Tel: +886-2-8787-1232
Fax: +886-2-8787-1239
Mail: info@allgenesis.com
Copyright © 2019 Allgenesis Biotherapeutics Inc. All rights reserved.